| アブストラクト | Drug-induced cardiotoxicity represents one of the most common causes of attrition of drug candidates in preclinical and clinical development. For this reason, the evaluation of cardiac toxicity is essential during drug development and regulatory review. In the present study, drug-induced postmarket adverse event combinations from the FDA Adverse Event Reporting System were extracted for 2002 drugs using 243 cardiac toxicity-related preferred terms (PTs). These PTs were combined into 12 groups based on their clinical relevance to serve as training sets. The optimal classification scheme was determined using a combination of data sources that included drug labeling information, published literature, clinical study data, and postmarket surveillance data. Two commercial QSAR platforms were used to construct 12 models, including general cardiac toxicity, cardiac ischemia, heart failure, cardiac valve disease, myocardial disease, pericardial disease, structural heart disease, cardiac arrhythmia, Torsades de Pointes, long QT syndrome, atrial fibrillation and ventricular arrhythmia, and cardiac arrest. The cross-validated performance for the new models reached a sensitivity of up to 80% and negative predictivity of up to 80%. These new models covering a wide range of cardiac endpoints will provide fast, reliable, and comprehensive predictions of potential cardiotoxic compounds in drug discovery and regulatory safety assessment. |
|---|
| ジャーナル名 | Chemical research in toxicology |
|---|
| Pubmed追加日 | 2024/11/13 |
|---|
| 投稿者 | Mou, Zhongyu; Volarath, Patra; Racz, Rebecca; Cross, Kevin P; Girireddy, Mounika; Chakravarti, Suman; Stavitskaya, Lidiya |
|---|
| 組織名 | FDA Center for Drug Evaluation and Research (CDER), Silver Spring, Maryland;20903, United States.;Instem, Columbus, Ohio 43215, United States.;MultiCASE, Inc., Mayfield Heights, Ohio 44124, United States. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39535830/ |
|---|
